ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

VTGN VistaGen Therapeutics Inc

4.55
0.14 (3.17%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
VistaGen Therapeutics Inc VTGN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.14 3.17% 4.55 23:00:08
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.47 4.31 4.55 4.50 4.41
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202407:30BWVistagen Announces Positive Results from Phase 2A Pilot..
09/4/202407:30BWVistagen to Present at the 2024 Anxiety and Depression..
01/4/202407:30BWVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol..
11/3/202407:30BWVistagen to Present at Stifel 2024 Virtual CNS Days
06/3/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
28/2/202407:30BWVistagen to Present at TD Cowen 44th Annual Health Care..
14/2/202417:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202407:56EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202415:52EDGAR2Form S-3 - Registration statement under Securities Act of..
13/2/202415:33EDGAR2Form 8-K - Current report
13/2/202415:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/2/202415:20BWVistagen Reports Fiscal 2024 Third Quarter Financial Results..
06/2/202407:30BWVistagen to Report Fiscal Year 2024 Third Quarter Financial..
03/1/202416:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202416:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202416:09EDGAR2Form 8-K - Current report
27/12/202307:30BWVistagen Receives Notice from European Patent Office of..
09/11/202315:44EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:42EDGAR2Form 8-K - Current report
09/11/202315:30BWVistagen Provides Corporate Update and Reports Fiscal 2024..
08/11/202307:30BWVistagen to Present at Stifel 2023 Healthcare Conference
07/11/202307:30BWVistagen to Present Positive Fasedienol Phase 3 Data and..
06/11/202320:46EDGAR2Form 8-K/A - Current report: [Amend]
06/11/202315:27EDGAR2Form 8-K - Current report
06/11/202307:00BWVistagen To Report Second Quarter Financial Results and Host..
03/11/202319:14EDGAR2Form 3 - Initial statement of beneficial ownership of..
26/10/202315:13EDGAR2Form 8-K - Current report
16/10/202315:37EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/10/202315:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/10/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202315:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/10/202315:47EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/10/202307:30BWVistagen to Present at Jefferies Inaugural Biotech CNS/Neuro..
04/10/202315:07EDGAR2Form 8-K - Current report
03/10/202315:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202306:30BWVistagen Announces Pricing of $100 Million Underwritten..
02/10/202306:15EDGAR2Form 8-K - Current report
29/9/202315:26EDGAR2Form 8-K - Current report
12/9/202307:30BWVistagen Announces Positive Results from Exploratory Phase..
08/9/202316:27EDGAR2Form 8-K - Current report
05/9/202308:00BWVistagen and Fuji Enter Exclusive Negotiation Agreement for..
23/8/202312:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202312:08EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/8/202307:40EDGAR2Form 8-K - Current report
22/8/202307:30BWVistagen Appoints Cindy Anderson as Chief Financial Officer

Su Consulta Reciente

Delayed Upgrade Clock